Benefit-Risk Assessment for New Drug and Biological Products; Draft Guidance for Industry; Availability

1 organizations filed 1 public comment on Benefit-Risk Assessment for New Drug and Biological Products; Draft Guidance for Industry; Availability, at the Food and Drug Administration. The comment window closed 1702d ago.

Commenters (1)

• Consumer Healthcare Products Associationtrade assoc.

  1 filing · confidence 97%